We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Indaptus Therapeutics Inc (INDP) USD0.01

Sell:$0.84 Buy:$0.90 Change: $0.0127 (1.51%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$0.84
Buy:$0.90
Change: $0.0127 (1.51%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$0.84
Buy:$0.90
Change: $0.0127 (1.51%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Contact details

Address:
3 Columbus Circle, 15Th Floor
NEW YORK
10019
United States
Telephone:
+1 (646) 4272727
Website:
https://indaptusrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
INDP
ISIN:
US45339J1051
Market cap:
$10.12 million
Shares in issue:
12.01 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jeffrey Meckler
    Chief Executive Officer, Director
  • Nir Sassi
    Chief Financial Officer, Treasurer, Secretary
  • Walt Linscott
    Chief Operating Officer
  • Michael Newman
    Chief Scientific Officer, Director
  • Roger Waltzman
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.